文献速递临床试验与 GCP真实世界研究与卫生经济

甲硝唑与乳酸治疗细菌性阴道病的比较(VITA):评估局部乳酸凝胶治疗第二发及后续发作细菌性阴道病临床与成本效益的随机对照试验方案

Metronidazole versus lactic acid for treating bacterial vaginosis (VITA): protocol for a randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis.
PubMed 文献 · Trials · 2019-11-27

VITA是一项开放标签、多中心、平行组随机对照试验,纳入临床诊断细菌性阴道病且过去2年内至少发作1次的女性,按1:1随机接受阴道内乳酸凝胶5 ml每日一次共7天或口服甲硝唑片400 mg每日两次共7天,随访6个月。估计样本量1900例,以检测乳酸凝胶组应答率绝对增加6%至86%。主要结局为第2周参与者报告的细菌性阴道病缓解。

要点

  • VITA为开放标签、多中心、平行组随机对照试验,比较乳酸凝胶与甲硝唑治疗复发性细菌性阴道病。
  • 乳酸凝胶用法为阴道内5 ml每日一次共7天,甲硝唑为口服400 mg每日两次共7天。
  • 主要结局为第2周参与者报告的细菌性阴道病缓解,估计样本量1900例。

核心结论

  • 该试验旨在研究乳酸凝胶相比甲硝唑治疗复发性细菌性阴道病是否具有临床有效性和成本效益。
  • 试验结果将有助于为英国细菌性阴道病治疗指南提供信息,并可能为复发性发作提供一种避免反复暴露于抗生素的替代有效治疗。

研究设计与样本

  • VITA是一项开放标签、多中心、平行组随机对照试验。
  • 纳入对象为临床诊断细菌性阴道病且过去2年内至少有一次细菌性阴道病发作的女性。
  • 参与者按1:1随机分配至阴道内乳酸凝胶5 ml每日一次共7天或口服甲硝唑片400 mg每日两次共7天。
  • 所有参与者随访6个月以评估健康状况和医疗费用,并对一个亚组进行访谈以进一步探索治疗的依从性、耐受性和可接受性。
  • 估计样本量为1900名参与者,以检测乳酸凝胶组应答率绝对增加6%至86%。

关键数值与推荐

  • 主要结局为第2周参与者报告的细菌性阴道病缓解。
  • 估计样本量1900名参与者,以检测应答率绝对增加6%至86%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bacterial vaginosis (BV) affects 30-50% of women at some time in their lives and is an embarrassing and distressing condition which can be associated with potentially serious comorbidities. Current antibiotic treatments such as metronidazole are effective but can result in side effects, and recurrence is common. This trial aims to investigate whether lactic acid gel is clinically effective and cost effective in the treatment of recurrent BV compared with metronidazole. METHODS: VITA is an open-label, multicentre, parallel group randomised controlled trial for women with a clinical diagnosis of BV and at least one previous BV episode in the past 2 years. Participants will be randomised 1:1 to intravaginal lactic acid gel 5 ml once daily for 7 days or oral metronidazole tablets 400 mg twice daily for 7 days. All participants will be followed up for 6 months to assess health status and healthcare costs. A subgroup will be interviewed to further explore adherence, tolerability and acceptability of treatment. The estimated sample size is 1900 participants to detect a 6% absolute increase in response rate to 86% in those receiving lactic acid gel. The primary outcome is participant-reported resolution of BV at Week 2. DISCUSSION: Results from this trial will help inform UK treatment guidelines for BV and may provide an alternative effective treatment for recurrent episodes of this condition which avoids repeated exposure to antibiotics. TRIAL REGISTRATION: ISRCTN, ISRCTN14161293. Registered on 8 September 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Armstrong-Buisseret L, Brittain C, David M, et al. Metronidazole versus lactic acid for treating bacterial vaginosis (VITA): protocol for a randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis. Trials. 2019. PMID: 31775859. doi:10.1186/s13063-019-3731-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。